Loefflers syndrome differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 169: | Line 169: | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Fever | |||
* Crackles | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Eosinophilia is prominent in the early stages of disease but minimal with established disease | * Eosinophilia is prominent in the early stages of disease but minimal with established disease | ||
Line 189: | Line 192: | ||
* Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | * Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | ||
| colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Fever | |||
* Crackles | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 213: | Line 219: | ||
* Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved. | * Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved. | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Fever | |||
* Crackles | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* <small>1500 cells/microL</small> | * <small>1500 cells/microL</small> | ||
Line 243: | Line 252: | ||
* History of initiation of a culprit medication two to six weeks prior to disease onset | * History of initiation of a culprit medication two to six weeks prior to disease onset | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Fever | |||
* Crackles | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 266: | Line 278: | ||
* Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases | * Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Fever | |||
* Crackles | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* ≥40 percent | * ≥40 percent | ||
Line 295: | Line 310: | ||
* Dyspnea, | * Dyspnea, | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Fever | |||
* Crackles | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* ≥25 percent | * ≥25 percent | ||
Line 329: | Line 347: | ||
|- | |- | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Sarcoidosis]] | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* +/- mild fever | |||
* Crackles | |||
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* [[Lymphadenopathy classification|Hilar]] [[lymphadenopathy]] | |||
* Lung infiltrates | |||
* Evidences of[[Interstitial lung disease|pulmonary fibrosis]] in sever cases | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Parenchymal perilymphatic [[nodules]]. | |||
* Honeycombing | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* [[Granulomas|Non-caseating granulomas]] | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 344: | Line 371: | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Crackles | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 356: | Line 385: | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Crackles | |||
| style="background: #F5F5F5; padding: 5px;" |<10 percent | | style="background: #F5F5F5; padding: 5px;" |<10 percent | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 15:08, 11 June 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.
Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||
Increased Eosinophil
count |
Other lab findings | CXR | CT Scan | |||||||||
Helminthic
and fungal infection-related eosinophilic lung diseases |
Transpulmonary
passage of larvae (Loffler's syndrome) |
|
|
|
| |||||||
Tropical
pulmonary eosinophilia |
|
|
|
|
|
| ||||||
Allergic bronchopulmonary aspergillosis |
|
|
Mild to moderate |
|
|
|||||||
Heavy
hematogenous seeding with helminths |
|
|
Mild to
moderate to high |
|
|
| ||||||
Pulmonary parenchymal invasion |
|
|
|
|
|
| ||||||
Nonhelminthic infections | Coccidioidomycosis |
|
|
|
||||||||
Mycobacterium tuberculosis | ||||||||||||
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) |
|
|
|
|
|
|
||||||
Drug- and toxin-induced eosinophilic lung diseases |
|
|
Mild to moderate |
| ||||||||
Chronic eosinophilic pneumonia |
|
|
|
|
|
|||||||
Idiopathic acute eosinophilic pneumonia |
|
|
|
|
|
| ||||||
Diseases | Symptom 1 | Symptom 2 | Physical exam 1 | Physical exam 2 | Increased Eosinophil count
(High) |
Other lab findings | CXR | CT Scan | Histopathology | Gold standard | Additional findings | |
Sarcoidosis |
|
Mild to moderate |
|
|
||||||||
Pulmonary Langerhans cell histiocytosis (Histiocytosis X) |
|
Mild to moderate | ||||||||||
Idiopathic pulmonary fibrosis |
|
<10 percent | ||||||||||
Differential Diagnosis 7 |